Drug pricing continues to dominate the health policy arena with a whirlwind of news spanning drug importation, cancer drug coverage and clinical trial data manipulation. A week after HHS announced a drug import initiative, the reality of how difficult it will be to execute that plan began to set in. Hospitals and oncologists scored a win on CAR-T coverage days after suffering a partial loss on Medicare payment for the pricey cancer drug. And the maker of the world’s most...